Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Drug ineffective
Clinical narrative: Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 38-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 02Sep2021 as dose 1, single (Lot number: FD8448), in left arm, on 23Sep2021 as dose 2, single (Lot number: FC3184), in right arm and on 08Apr2022 as dose 3 (booster), single (Lot number: FK9894) at the age of 38 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Seasonal allergies" (unspecified if ongoing), notes: Seasonal allergies; "Food intolerances are: soy, corn, wheat, peanuts (causes stomach pa" (unspecified if ongoing), notes: Food intolerances are: soy, corn, wheat, peanuts (causes stomach pain); "Food intolerances are: soy, corn, wheat, peanuts (causes stomach pa" (unspecified if ongoing), notes: Food intolerances are: soy, corn, wheat, peanuts (causes stomach pain); "Food intolerances are: soy, corn, wheat, peanuts (causes stomach pa" (unspecified if ongoing), notes: Food intolerances are: soy, corn, wheat, peanuts (causes stomach pain); "Food intolerances are: soy, corn, wheat, peanuts (causes stomach pa" (unspecified if ongoing), notes: Food intolerances are: soy, corn, wheat, peanuts (causes stomach pain); "Food intolerances are: soy, corn, wheat, peanuts (causes stomach pa" (unspecified if ongoing), notes: Food intolerances are: soy, corn, wheat, peanuts (causes stomach pain); "Bipolar disorder" (unspecified if ongoing); "IBS/Gerds" (unspecified if ongoing), notes: IBS/Gerds; "IBS/Gerds" (unspecified if ongoing), notes: IBS/Gerds; "Asthma" (unspecified if ongoing); "Sleep assist" (unspecified if ongoing), notes: Sleep assist. Concomitant medication(s) included: SEROQUEL taken for bipolar disorder, start date: 16Feb2022; ONDANSETRAN taken for inflammatory bowel disease, gastrooesophageal reflux disease, start date: 10Feb2022; SYMBICORT taken for asthma, start date: 07Jan2022; SINGULAIR taken for asthma, start date: 21Nov2021; ALBUTEROL [SALBUTAMOL] taken for asthma, start date: 02Sep2021; DICYCLOMINE taken for inflammatory bowel disease, start date: 02Sep2021; PROTONIX [OMEPRAZOLE] taken for gastrooesophageal reflux disease, start date: 02Sep2021; LOMOTIL [LOPERAMIDE HYDROCHLORIDE] taken for bipolar disorder, start date: 02Sep2021; CLONIDINE taken for sleep disorder, start date: 02Sep2021; TOPOMOX taken for bipolar disorder, start date: 02Sep2021; LAMICTAL taken for bipolar disorder, start date: 02Sep2021. Past drug history included: Amoxicillin, reaction(s): "Known Allergies: Drug allergy", notes: Known Allergies: Amoxicillin. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset May2022, outcome "unknown" and all described as "Treatment of COVID-19". Therapeutic measures were taken as a result of drug ineffective, covid-19. Clinical course: Anti-viral medication details for COVID 19 Treatment included Nirmatrelvir-ritonavir (Paxlovid), Treatment start date was 28May2022, treatment stop date was 01Jun2022, Lot number: 81-6036-9504 and Indication was treatment of COVID-19. Other medication received included Vitamins with brand D3 20,000 IUs, B12 10,000 IUs, Quercetin 2000mg, Nutricost n-acetyl L-tyrosine, all with start date 15May2022.